Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-11-04 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 3290 | $25.00 - $25.00 | $82,250 |
| 2024-11-04 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 3290 | $9.57 - $9.57 | $31,485 |
| 2024-11-01 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 5760 | $24.28 - $24.28 | $139,866 |
| 2024-11-01 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 5760 | $1.86 - $1.86 | $10,713 |
| 2024-11-01 | Nurix Therapeutics, Inc. | van Houte Hans
(Chief Financial Officer) |
S | Common Stock | D | 3546 | $24.28 - $24.28 | $86,083 |
| 2024-10-30 | Nurix Therapeutics, Inc. | van Houte Hans
(Chief Financial Officer) |
S | Common Stock | D | 2368 | $24.30 - $24.30 | $57,554 |
| 2024-10-30 | Nurix Therapeutics, Inc. | van Houte Hans
(Chief Financial Officer) |
M | Common Stock | A | 8636 | $0.00 - $0.00 | $0 |
| 2024-10-30 | Nurix Therapeutics, Inc. | Hansen Gwenn
(Chief Scientific Officer) |
S | Common Stock | D | 3437 | $24.30 - $24.30 | $83,536 |
| 2024-10-30 | Nurix Therapeutics, Inc. | Hansen Gwenn
(Chief Scientific Officer) |
M | Common Stock | A | 8957 | $0.00 - $0.00 | $0 |
| 2024-10-30 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 4182 | $24.30 - $24.30 | $101,643 |
| 2024-10-30 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 7674 | $0.00 - $0.00 | $0 |
| 2024-10-14 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 3290 | $25.00 - $25.00 | $82,250 |
| 2024-10-14 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 3290 | $9.57 - $9.57 | $31,485 |
| 2024-10-01 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 5760 | $22.19 - $22.81 | $128,017 |
| 2024-10-01 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 5760 | $1.86 - $1.86 | $10,713 |
| 2024-08-26 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 9870 | $25.01 - $25.01 | $246,842 |
| 2024-08-26 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 9870 | $1.86 - $9.57 | $60,045 |
| 2024-08-26 | Nurix Therapeutics, Inc. | van Houte Hans
(Chief Financial Officer) |
S | Common Stock | D | 20000 | $25.22 - $25.22 | $504,370 |
| 2024-08-01 | Nurix Therapeutics, Inc. | van Houte Hans
(Chief Financial Officer) |
S | Common Stock | D | 3477 | $21.43 - $22.22 | $74,575 |
| 2024-08-01 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 5760 | $21.39 - $22.18 | $123,457 |
| 2024-08-01 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 5760 | $1.86 - $1.86 | $10,713 |
| 2024-07-30 | Nurix Therapeutics, Inc. | Hansen Gwenn
(Chief Scientific Officer) |
S | Common Stock | D | 3408 | $20.67 - $20.67 | $70,435 |
| 2024-07-30 | Nurix Therapeutics, Inc. | Hansen Gwenn
(Chief Scientific Officer) |
M | Common Stock | A | 8957 | $0.00 - $0.00 | $0 |
| 2024-07-30 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 2920 | $20.67 - $20.67 | $60,349 |
| 2024-07-30 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 7674 | $0.00 - $0.00 | $0 |
| 2024-07-30 | Nurix Therapeutics, Inc. | van Houte Hans
(Chief Financial Officer) |
S | Common Stock | D | 2490 | $20.67 - $20.67 | $51,462 |
| 2024-07-30 | Nurix Therapeutics, Inc. | van Houte Hans
(Chief Financial Officer) |
M | Common Stock | A | 8636 | $0.00 - $0.00 | $0 |
| 2024-07-17 | Nurix Therapeutics, Inc. | Kunkel Lori Anne
(Director) |
G | Common Stock | D | 54027 | $0.00 - $0.00 | $0 |
| 2024-07-01 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 5760 | $20.68 - $21.57 | $119,836 |
| 2024-07-01 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 5760 | $1.86 - $1.86 | $10,713 |
| 2024-06-20 | Nurix Therapeutics, Inc. | van Houte Hans
(Chief Financial Officer) |
S | Common Stock | D | 20000 | $20.01 - $20.01 | $400,216 |
| 2024-06-13 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 1864 | $17.02 - $17.02 | $31,721 |
| 2024-06-13 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 1864 | $1.86 - $1.86 | $3,467 |
| 2024-06-12 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 1900 | $17.01 - $17.01 | $32,319 |
| 2024-06-12 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 1900 | $1.86 - $1.86 | $3,534 |
| 2024-06-05 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 400 | $17.00 - $17.00 | $6,801 |
| 2024-06-05 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 400 | $1.86 - $1.86 | $744 |
| 2024-06-03 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
S | Common Stock | D | 1596 | $17.01 - $17.01 | $27,152 |
| 2024-06-03 | Nurix Therapeutics, Inc. | Ring Christine
(Chief Legal Officer) |
M | Common Stock | A | 1596 | $1.86 - $1.86 | $2,968 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |